By acquiring Serenex Inc. for an undisclosed sum, Pfizer Inc. gets one of only two oral heat shock protein 90 inhibitors in the clinic for cancer. As a bonus, the pharma company also gets Serenex's matrix technology that identifies proteins in the purine-binding proteome, and a library of about 5,000 purine-binding proteins, including Hsp90s.

Hsp90 is a molecular chaperone that regulates the folding and degradation of proteins involved in cell growth and survival. These signaling proteins play key roles in cancer, inflammation and neurodegenerative diseases.